St. Joseph's Hospital and Medical Center, Phoenix
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, St. Joseph's Hospital and Medical Center, Phoenix sits in the top decile of US sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count).
St. Joseph's Hospital and Medical Center, Phoenix: 44 sponsored US clinical trials, 8 recruiting.
St. Joseph's Hospital and Medical Center, Phoenix sponsors 44 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 24 completed. 7 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mild Cognitive Impairment (MCI), with 2 trials.
Top-decile sponsor footprint
St. Joseph's Hospital and Medical Center, Phoenix ranks in the top decile of sponsors by registered trial count (#407 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
24 of 36 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (66.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
44 total, page 1 of 1
Repurposing Siponimod for Alzheimer's Disease
NCT06639282
Working Memory Training in Patients with Mild Cognitive Impairment
NCT06734286
PREVENT ALL ALS Study
NCT06581861
ASSESS ALL ALS Study
NCT06578195
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
NCT06072586
Gentamicin Bladder Instillation on CAUTI
NCT06332040
Time Restricted Eating in Alzheimer's Disease
NCT06429124
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
NCT03014687
Exercise in Advanced Parkinson's Disease (PD) With Deep Brain Stimulation (DBS)
NCT05204680
Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)
NCT05276349
DBS of Posterior Subthalamic Area (PSA) and Ventral Intermediate Nucleus (VIM) in Essential Tremor (ET)
NCT05096572
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
NCT04032626
A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection
NCT03834740
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
NCT03474614
Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)
NCT02759887
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
NCT02924194
Post-Operative Water Load Following Transsphenoidal Pituitary Surgery
NCT02727686
Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
NCT02605746
Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia
NCT03088592
A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population
NCT02618382
Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury
NCT02495545
Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery
NCT02276911
Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury
NCT02389647
Identification of Genomic Changes in Families Having Multiple Members With Tumors
NCT02386241
Micro Ribonucleic Acid (miRNA) Markers of Hydrocephalus in Intraventricular Hemorrhage (IVH)
NCT02386228
Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
NCT02351700
Transsphenoidal Extent of Resection Study
NCT02357498
Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Parkinson's Disease
NCT02401308
A Phase 0 Study of AZD1775 in Recurrent GBM Patients
NCT02207010
Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
NCT02046187
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
NCT02085304
Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device
NCT03088579
Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI
NCT01870518
Evaluating the Impact That Personnel Traffic Through the Operating Room Has on Surgical Site Infections
NCT01783769
DBS Under General Anesthesia: Comparison To The Standard Technique
NCT01997398
Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
NCT01832350
Dural Graft Equivalent Comparison Trial
NCT01667770
Rhinological Outcomes in Endonasal Pituitary Surgery
NCT01504399
Fluorescence-guided Surgery for Low- and High-grade Gliomas
NCT01502280
Barrow Nasal Inventory Survey
NCT01322945
Identification of Novel Molecular Markers for Vasospasm
NCT02389634
Chlorhexidine Gluconate Oral Care for Adults Experiencing Trauma
NCT01382446
Effects of Oral Care in the Neuroscience ICU
NCT00518752
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
NCT00318474
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 4 |
| Phase 3 | 2 |
| Phase 4 | 5 |
What is open in the St. Joseph's Hospital and Medical Center, Phoenix pipeline
8 recruiting of 44 indexed (18% open); 24 completed (55%).
Phase mix: 7 late (III/IV) vs 10 early (I/II) (balanced across stages).
Top condition: Mild Cognitive Impairment (MCI) (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
St. Joseph's Hospital and Medical Center, Phoenix: open-pipeline peers nationwide
Peers matched on 44 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
St. Joseph's Hospital and Medical Center, Phoenix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 44 trials (± recruiting share)
- Agios Pharmaceuticals · 44 trials · 7% recruiting
- Beth Israel Medical Center · 44 trials · 0% recruiting
- Innovative Medical · 44 trials · 0% recruiting
- Kowa Research Institute · 44 trials · 0% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Burke Medical Research Institute · 18% recruiting · 11 trials
- Grand Valley State University · 18% recruiting · 11 trials
- Imunon · 18% recruiting · 11 trials
- InventisBio Co. · 18% recruiting · 11 trials
Related
What to do with this St. Joseph's Hospital and Medical Center, Phoenix page
44 registered trials is a research-attention snapshot, not an endorsement of St. Joseph's Hospital and Medical Center, Phoenix or any single study.
- 8 of St. Joseph's Hospital and Medical Center, Phoenix's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Mild Cognitive Impairment (MCI) is the condition St. Joseph's Hospital and Medical Center, Phoenix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Mild Cognitive Impairment (MCI) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
St. Joseph's Hospital and Medical Center, Phoenix pipeline card: 44 registered trials from official public datasets.Report a data error.